Ahaan Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ahaan Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $421.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ahaan Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $421.1K Trade | TransData Nexus

Ahaan Healthcare Private Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $421.1K Total Trade · DGFT Verified

Ahaan Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $421.1K across 3 products in 3 therapeutic categories. Based on 22 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Domperidone ($310.7K), Terbutaline ($95.3K), Niacin ($15.1K).

Ahaan Healthcare Private Limited — Export Portfolio & Destination Treemap

Ahaan Healthcare Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ahaan Healthcare Private Limited? — Company Overview & Market Position

Ahaan Healthcare Private Limited (AHPL) is a privately held pharmaceutical company incorporated on November 1, 2007, in Satara, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U15139PN2007PTC130947. AHPL specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. As of the latest available data, AHPL is led by directors Yatin Narayandas Doshi, Supriya Yatin Doshi, and Mohini Narayandas Doshi.

The company's registered office is located at C/o Mr. Yatin Doshi, 1, Tulsi Vihar, Visawa Park, Satara, Maharashtra, 415001, India. AHPL's website, www.ahpl.co, provides further information about its products and services. The company has been operational for over 18 years, focusing on the production and export of pharmaceutical formulations across various therapeutic categories.

What Does Ahaan Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Domperidone$310.7K

Product Portfolio — Top 3 by Export Value

Ahaan Healthcare Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Domperidone	Gastrointestinal	$310.7K	7	1.0%	14
2	Terbutaline	Respiratory & OTC	$95.3K	11	2.7%	5
3	Niacin	Lipid & Metabolism	$15.1K	4	0.4%	11

Ahaan Healthcare Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $421.1K. The top category is Gastrointestinal (73.8% of portfolio), followed by Respiratory & OTC (22.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Ahaan Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

AHPL operates a state-of-the-art manufacturing facility in Satara, Maharashtra, designed to meet WHO Good Manufacturing Practice (GMP) standards. The plant is equipped with ultramodern equipment and machinery, enabling the production of a wide range of dosage forms, including tablets, hard and soft gelatin capsules, dry and liquid syrups, dry and liquid injectables, prefilled syringes, large volume parenterals, eye and ear drops, as well as herbal, nutraceutical, dermatological, hormonal, and cosmeceutical products. (ahpl.co)

3Key Leadership

The leadership team at AHPL comprises directors Yatin Narayandas Doshi, Supriya Yatin Doshi, and Mohini Narayandas Doshi. Yatin Narayandas Doshi has been serving as a director since November 1, 2007, while Supriya Yatin Doshi joined the board on June 7, 2010, and Mohini Narayandas Doshi on January 1, 2014. Specific roles and responsibilities within the company are not detailed in the available sources.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ahaan Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

AHPL's export portfolio includes finished pharmaceutical formulations across three therapeutic categories: gastrointestinal (73.8%), respiratory & OTC (22.6%), and lipid & metabolism (3.6%). The company's top three products are Domperidone ($311K, Rank #14, 1.0% market share), Terbutaline ($95K, Rank #5, 2.7% market share), and Niacin ($15K, Rank #11, 0.4% market share). These figures indicate a focus on gastrointestinal and respiratory treatments, with a significant presence in the respiratory & OTC segment.

2Emerging Markets

AHPL's export data does not specify its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's export strategy appears to be concentrated in markets where its top products have established demand, particularly in the gastrointestinal and respiratory therapeutic areas.

3Geographic Strategy

The company's export strategy is concentrated on a select range of products, with the top three products accounting for 100% of the export value. This indicates a high level of portfolio concentration, which may expose AHPL to risks associated with market fluctuations in these specific therapeutic areas. Diversifying the product portfolio and exploring new geographic markets could mitigate such risks and enhance the company's market resilience.

Ahaan Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding AHPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. Given the company's focus on finished pharmaceutical formulations, obtaining FDA approvals would be essential for accessing the U.S. market. It is recommended to verify the current status of these regulatory approvals directly with the FDA or through AHPL's official communications.

2WHO & EU GMP

AHPL's manufacturing facility is WHO GMP certified, ensuring compliance with international quality standards for pharmaceutical manufacturing. However, specific details regarding EU GMP certification or EDQM status are not available in the provided sources. Securing EU GMP certification would be crucial for market access within the European Union.

3CDSCO & Indian Regulatory

AHPL holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facility is located in Satara, Maharashtra, and is subject to inspections and approvals by the state drug controller. Specific details regarding export No Objection Certificates (NOCs) are not available in the provided sources.

Ahaan Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the gastrointestinal and respiratory therapeutic segments, AHPL faces competition from both domestic and international pharmaceutical companies. While specific market share data for competitors is not available, the company's focus on a limited product portfolio may position it as a niche player in these segments. Expanding the product range and enhancing market presence could improve competitiveness.

2Key Differentiators

AHPL's key differentiators include its WHO GMP certified manufacturing facility, which ensures adherence to international quality standards, and its specialization in a select range of therapeutic categories, particularly gastrointestinal and respiratory treatments. These strengths enable the company to offer high-quality products tailored to specific market needs.

3Strategic Position

AHPL's current strategic direction appears to be focused on the production and export of generic pharmaceutical formulations in the gastrointestinal and respiratory segments. The company's future outlook would benefit from diversifying its product portfolio, exploring new therapeutic areas, and expanding into emerging markets to enhance growth and reduce dependency on a limited product range.

Buyer Due Diligence Brief — Evaluating Ahaan Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

AHPL's track record in manufacturing and exporting pharmaceutical formulations is supported by its WHO GMP certification, indicating a commitment to quality and reliability. The company's export volume and consistency are not detailed in the available sources, but the focus on a select range of products suggests a strategic approach to market penetration. Reliability indicators such as on-time delivery and adherence to quality standards are not specified but can be inferred from the company's certifications and product offerings.

2Certifications to Verify

Importers should verify the following certifications when considering AHPL as a supplier:

FDA Approval: To ensure compliance with U.S. regulatory standards for pharmaceutical products. Verification can be done through the FDA's official website or by contacting AHPL directly.

WHO GMP Certification: To confirm adherence to international manufacturing standards. This can be verified through the World Health Organization's official channels.

Frequently Asked Questions — Ahaan Healthcare Private Limited

How many pharmaceutical products does Ahaan Healthcare Private Limited export from India?

Ahaan Healthcare Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Domperidone ($310.7K), Terbutaline ($95.3K), Niacin ($15.1K). Total export value is $421.1K.

What is Ahaan Healthcare Private Limited's total pharmaceutical export value?

Ahaan Healthcare Private Limited's total pharmaceutical export value is $421.1K, based on 22 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ahaan Healthcare Private Limited cover?

Ahaan Healthcare Private Limited exports across 3 therapeutic categories. The largest are Gastrointestinal (73.8%, 1 products), Respiratory & OTC (22.6%, 1 products), Lipid & Metabolism (3.6%, 1 products).

Get Full Ahaan Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.